Kura Oncology announces issuance of patent for tipifarnib in head, neck cancer
Kura Oncology announced that the United States Patent and Trademark Office has issued a patent protecting the company's lead product candidate, tipifarnib, which is currently being studied in multiple Phase 2 clinical trials. The patent includes multiple claims directed to the use of tipifarnib in patients with HRAS mutant squamous cell carcinoma of the head and neck and has an expiration date of August 2036, excluding any possible patent term extension. "Our goal is to identify genetically-defined patient populations in which tipifarnib will demonstrate enhanced therapeutic activity and to pursue patent protection in those indications," said Troy Wilson, Ph.D., President and CEO of Kura Oncology. "The granting of this new patent is a major milestone for Kura, and it illustrates the potential of our broader strategy to generate intellectual property related to tipifarnib and its use in treating human diseases." U.S. Patent No. 9,707,221, entitled "Methods of Treating Cancer Patients with Farnesyltransferase Inhibitors" is directed to the use of tipifarnib for treating patients with relapsed and/or refractory HRAS SCCHN.